ELYM - Eliem Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

154.1M

Cash

105M

Avg Qtr Burn

-1.81M

Short % of Float

6.56%

Insider Ownership

10.42%

Institutional Own.

64.01%

Qtr Updated

03/31/24

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
ETX-810 Details Chronic pain, Pain, Sciatica	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ETX-810 Details Chronic pain, Sciatica , Pain, Diabetes	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ETX-155 Details Epilepsy	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ETX-123 (Kv7.2/3 channel opener) Details Epilepsy, Pain, Seizures	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ETX-155 Details Major depressive disorder, Perimenopausal Depression	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.